세계의 급성 근긴장이상증 시장 : 약제 클래스별, 연령층별, 유통 채널별, 지역별.

The global acute dystonia market was valued US$ 120.7 Mn in 2023 and is expected to reach US$ 155.0 Mn by 2031 growing at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

Figure 1. Global Acute Dystonia Market Share (%), By Region, 2024

Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:

• Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
• Idiopathic Dystonia: Where the cause is unknown
• Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke

Market Dynamics:

The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2023, according to a report published by the World Health Organization (WHO), Parkinson's disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.

Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global acute dystonia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market

Detailed Segmentation:

• Global Acute Dystonia Market, By Drug Class
  • Anticholinergic Agents
  • Benzodiazepines
  • Others (Neurotoxin, etc.)
• Global Acute Dystonia Market, By Age Group
  • Children
  • Adult
• Global Acute Dystonia Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Acute Dystonia Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Top Companies in the Global Acute Dystonia Market:
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F.Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Age Group
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of dystonia
  • Side effects associated with drugs
  • Understanding changing treatment patterns
• Key Highlights
• Regulatory Guidelines
• Market Trends
• PEST Analysis
• Investments and Funding
• Mergers, Acquisitions, and Collaborations
• Product Mapping
• Identification of Top Market Players
• Adoption of Various Business Development Strategies by the Market players
• Healthcare Spending by Country

4. Global Acute Dystonia Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Acute Dystonia Market, By Drug Class, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Anticholinergic Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Others (Neurotoxin, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Acute Dystonia Market, By Age Group, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Children
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Acute Dystonia Market, By Distribution Channel, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Acute Dystonia Market, By Region, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020 - 2031
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Company Profile
  • Fresenius Kabi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
• Analyst Views

10. Section

• References
• Research Methodology
• About us